Alzheimer’s disease affects millions of people worldwide, and as the world’s population ages, that number is going up. But, the exact cause of Alzheimer’s…
As of a landmark policy change in October 2023, Medicare now covers PET scans to look for Alzheimer’s biomarker beta-amyloid in the brain for…
Today in the United Kingdom, people who are concerned they may be showing the early signs of Alzheimer’s disease or another form of dementia…
The science behind Alzheimer’s is constantly developing, but its cause remains elusive and the disease is frequently misdiagnosed. A 2017 study at a hospital…
A new generation of Alzheimer’s treatments — groundbreaking, disease-modifying monoclonal antibody drugs — is on the rise, and two so far have hit the…
Some 65 percent of adults over the age of 60 live with hearing loss — and mounting research shows it is a controllable risk…
As Dr. Jeff Chen MD, MBA recalled in a recent talk at the 2023 TED Conference in Vancouver, BC, when he was a medical…
Today, more than 55 million people are living with Alzheimer’s disease globally. In the U.S., one in 10 people over the age of 65,…
Over 30 million people live with Alzheimer’s disease worldwide, making it the most common form of dementia. Two thirds of those diagnoses are women….
According to drugmaker Eli Lilly, the FDA has rejected the company’s application for the FDA’s “Accelerated Approval” designation for experimental Alzheimer’s drug donanemab. The…
Update 27 January, 2023: In January 2023, lecanemab was granted accelerated approval by the FDA and made available to patients under the brand name…
Mild cognitive impairment (MCI), the condition associated with early stages of Alzheimer’s disease and related forms of dementia (like vascular dementia or Lewy Body…
Most Alzheimer’s treatments on the market today help manage symptoms, like memory loss — but they don’t get at the root cause. Roche hoped their…
November is National Alzheimer’s Disease Awareness Month. In an October 31, 2022 statement from the White House, President Joseph R. Biden, Jr. reminds the…
Researchers in Tokyo continue encouraging research on oxytocin as a potential Alzheimer’s drug target. When administered nasally, the hormone appeared to reverse cognitive decline…